Tag: Adlarity

FDA, Regulations

FDA Approves Adlarity (donepezil transdermal system) for Treatment of Patients with Alzheimer’s Disease

March 14, 2022


Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the U.S. Food and Drug Administration (FDA) has approved Corium’s Adlarity (donepezil transdermal system) as a treatment for patients with […]